MedKoo Cat#: 597471 | Name: p2Ca Peptide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

p2Ca Peptide is a self-peptide derived from the enzyme alpha-ketoglutarate dehydrogenase.

Chemical Structure

p2Ca Peptide
p2Ca Peptide
CAS#142606-55-1

Theoretical Analysis

MedKoo Cat#: 597471

Name: p2Ca Peptide

CAS#: 142606-55-1

Chemical Formula: C47H66N8O12

Exact Mass: 934.4800

Molecular Weight: 935.08

Elemental Analysis: C, 60.37; H, 7.11; N, 11.98; O, 20.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
p2Ca Peptide; Lspfpfdl; p2Ca-Y4;
IUPAC/Chemical Name
L-leucyl-L-seryl-L-prolyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-aspartyl-L-leucine
InChi Key
RLTLDVPHEYUGFZ-QSVFAHTRSA-N
InChi Code
InChI=1S/C47H66N8O12/c1-27(2)21-31(48)40(59)53-36(26-56)46(65)55-20-12-18-38(55)44(63)51-34(24-30-15-9-6-10-16-30)45(64)54-19-11-17-37(54)43(62)50-32(23-29-13-7-5-8-14-29)41(60)49-33(25-39(57)58)42(61)52-35(47(66)67)22-28(3)4/h5-10,13-16,27-28,31-38,56H,11-12,17-26,48H2,1-4H3,(H,49,60)(H,50,62)(H,51,63)(H,52,61)(H,53,59)(H,57,58)(H,66,67)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1
SMILES Code
CC(C)C[C@@H](C(O)=O)NC([C@H](CC(O)=O)NC([C@H](CC1=CC=CC=C1)NC([C@H]2N(C([C@H](CC3=CC=CC=C3)NC([C@H]4N(C([C@H](CO)NC([C@H](CC(C)C)N)=O)=O)CCC4)=O)=O)CCC2)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 935.08 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hornell TM, Martin SM, Myers NB, Connolly JM. Peptide length variants p2Ca and QL9 present distinct conformations to L(d)-specific T cells. J Immunol. 2001 Oct 15;167(8):4207-14. PubMed PMID: 11591741. 2: Dutz JP, Tsomides TJ, Kageyama S, Rasmussen MH, Eisen HN. A cytotoxic T lymphocyte clone can recognize the same naturally occurring self peptide in association with a self and nonself class I MHC protein. Mol Immunol. 1994 Sep;31(13):967-75. PubMed PMID: 8084337. 3: Wada H, Ono T, Uenaka A, Monden M, Nakayama E. Requirement of CD4+ T cells and antigen-presenting cells for primary in vitro generation of CD8+ cytotoxic T cells against Ld-binding self-peptide p2Ca. Immunology. 1995 Apr;84(4):633-7. PubMed PMID: 7790038; PubMed Central PMCID: PMC1415149. 4: Tjoa BA, Kranz DM. Sequence restrictions in T cell receptor beta-chains that have specificity for a self-peptide/Ld complex. Mol Immunol. 1994 Jul;31(10):705-11. PubMed PMID: 7518567. 5: Wu MX, Tsomides TJ, Eisen HN. Tissue distribution of natural peptides derived from a ubiquitous dehydrogenase, including a novel liver-specific peptide that demonstrates the pronounced specificity of low affinity T cell reactions. J Immunol. 1995 May 1;154(9):4495-502. PubMed PMID: 7536771. 6: Holler PD, Lim AR, Cho BK, Rund LA, Kranz DM. CD8(-) T cell transfectants that express a high affinity T cell receptor exhibit enhanced peptide-dependent activation. J Exp Med. 2001 Oct 15;194(8):1043-52. PubMed PMID: 11602635; PubMed Central PMCID: PMC2193521. 7: Goldstein J, Mostowsky H, Tung J, Hon H, Brunswick M, Kozlowski S. Naive alloreactive CD8 T cells are activated by purified major histocompatibility complex class I and antigenic peptide. Eur J Immunol. 1997 Apr;27(4):871-8. PubMed PMID: 9130638. 8: Jones LL, Colf LA, Stone JD, Garcia KC, Kranz DM. Distinct CDR3 conformations in TCRs determine the level of cross-reactivity for diverse antigens, but not the docking orientation. J Immunol. 2008 Nov 1;181(9):6255-64. PubMed PMID: 18941216; PubMed Central PMCID: PMC2598777. 9: Rivas FV, O'Herrin S, Gajewski TF. CD28 is not required for c-Jun N-terminal kinase activation in T cells. J Immunol. 2001 Sep 15;167(6):3123-8. PubMed PMID: 11544297. 10: Pawlowski TJ, Singleton MD, Loh DY, Berg R, Staerz UD. Permissive recognition during positive selection. Eur J Immunol. 1996 Apr;26(4):851-7. PubMed PMID: 8625978.